Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler has maintained an Equal-Weight rating on Amicus Therapeutics (NASDAQ:FOLD) and lowered the price target from $15 to $14.
October 10, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Amicus Therapeutics and lowered the price target from $15 to $14.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of Amicus Therapeutics in the short term as it indicates a lower valuation of the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100